Poliovirus capsid antigenic site

Poliovirus capsid antigenic site refers to specific surface-exposed regions on the capsid of poliovirus that are recognized by neutralizing antibodies produced during infection or vaccination. The **poliovirus capsid** is comprised of four structural proteins (VP1, VP2, VP3, VP4), with most antigenic sites localized in variable loops of VP1, VP2, and VP3 that are accessible to the immune system[2][4]. These antigenic sites are key determinants of viral neutralization: when antibodies bind to these regions, they can block viral attachment to the host cell (via the poliovirus receptor, CD155) or prevent entry/uncoating[1][3][4]. There are multiple described antigenic (neutralizing) sites (notably NAg sites 1, 2, 3a, and 3b), and these can vary among different serotypes and under immune pressure, though overall evolution is constrained by the requirement for the virus to maintain infectivity[1]. Mutations in these sites can contribute to vaccine escape or altered antigenicity—a major consideration in vaccine design and monitoring[1][4][5]. No approved small molecule drugs directly target these sites, but inactivated and live vaccines, as well as experimental monoclonal antibodies, exert their protective effect through antibody targeting of these capsid antigenic sites[1][4]. Monitoring antibody responses to these sites serves as a biomarker of immunity and vaccine efficacy. The main therapeutic challenge is antigenic drift/mutation in these regions, potentially compromising immunity in areas where the virus circulates under vaccine pressure[1][4][5].

Other names

poliovirus neutralizing antigenic sitepoliovirus capsid antigenic domainpoliovirus antigenic epitope

Neutralization of virus by preventing cell entry (antibodies binding to antigenic sites block virus interaction with host receptor and/or genome uncoating)